Scholarlink

<p>The future of hypertension management lies in distinguishing disease subtypes for precise control. The underlying drivers and pathology of non-obese hypertension (J-HTN) remain unclear. There is a lack of biomarkers for the early identification of J-HTN. The aim of this study was to identify circulating metabolomic profiles that facilitate the early detection of J-HTN patients, thereby providing valuable insights for more targeted and precision-based therapies. A non-targeted metabolomics approach was used to quantify serum metabolites in 120 patients with newly diagnosed hypertension, and to determine the metabolomic characteristics of J-HTN and two types of obese hypertension (fat-dominant and muscle-dominant). 4 metabolites unique to J-HTN were identified, with lysophosphatidylcholine 22:6 (LysoPC(22:6/0:0)) standing out as the marker showing the most pronounced difference. Using the serum metabolome alone, we were able to distinguish J-HTN from other hypertensive patients. In a secondary validation with an independent cohort of 60 medically treated J-HTN patients, 3 metabolites, including LysoPC(22:6/0:0), remained significantly altered. The serum metabolic profiles identified in this study enable the early detection of J-HTN, with LysoPC(22:6/0:0) emerging as a highly promising biomarker. This metabolite may also correlate with the clinical efficacy of J-HTN treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of serum metabolic markers in non-obese hypertensive patients using non-targeted metabolomics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月26日

查看全文
  • Yifan Xu,
  • Yilin Jiang,
  • Jia Lu,
  • Chen Xu,
  • Qing Li,
  • Hongjun Zhu

摘要

The future of hypertension management lies in distinguishing disease subtypes for precise control. The underlying drivers and pathology of non-obese hypertension (J-HTN) remain unclear. There is a lack of biomarkers for the early identification of J-HTN. The aim of this study was to identify circulating metabolomic profiles that facilitate the early detection of J-HTN patients, thereby providing valuable insights for more targeted and precision-based therapies. A non-targeted metabolomics approach was used to quantify serum metabolites in 120 patients with newly diagnosed hypertension, and to determine the metabolomic characteristics of J-HTN and two types of obese hypertension (fat-dominant and muscle-dominant). 4 metabolites unique to J-HTN were identified, with lysophosphatidylcholine 22:6 (LysoPC(22:6/0:0)) standing out as the marker showing the most pronounced difference. Using the serum metabolome alone, we were able to distinguish J-HTN from other hypertensive patients. In a secondary validation with an independent cohort of 60 medically treated J-HTN patients, 3 metabolites, including LysoPC(22:6/0:0), remained significantly altered. The serum metabolic profiles identified in this study enable the early detection of J-HTN, with LysoPC(22:6/0:0) emerging as a highly promising biomarker. This metabolite may also correlate with the clinical efficacy of J-HTN treatments.